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An increasing number of patients with diabetic nephropathy
has entered dialysis programs [I]. In this group of patients,
peritoncal dialysis secms to lead to lower morbidity than
intermittent hemodialysis 12, 31. Also in the treatment of acutc
renal thilure in critically ill patients, peritoneal dialysis may he
superior to hemodialysis 141, and by continuous trcatmcnt onc
can improve thc nutritional supply procedure and thereby
benefit the patient 151. Glucose, amino acids, and insulin
supplied to the peritoneal cavity would also improve nutritional
support. Clinically thc pcritoncal mcmbranc cannot only bc
used for dialysis hut also as a delivery site for nutritional agents.
During continuous peritoneal dialysis (CAPD), insulin sup-
plied in the dialysatc influcnccs blood glucosc rcgulation 6!.
Although this result indicates transperitoneal insulin transport,
quantitative studies on intraperitoncal insulin absorption relat-
ed to dwcll-time in patients treated with continuous peritoneal
dialysis are lacking.
The aim of this investigation was to study: (1) insulin regula-
tion of blood glucose when administered continuously via
dialysate during CAPD versus when given intermittently and
subcutaneously before CAPD; (2) the degree of ('251)insulin
retention in plastic CAPD bags aftcr complctc drainagc of thc
dialysis fluid: (3) absorption of('251)insulin from the dialysate in
the peritoneal cavity of diabetic and nondiahctic patients treat-
cd with CAPD.
Methods
Patient description (i/id insulin dosage. A total of six pa-
tients, three diabetics and three nondiahetics, all with glomeru-
lonephritis wcrc selccted for this invcstigation. One patient was
ancphric, the others were anuric or oliguric. 'I'hc mcan agc was
50 years (40 to 56), and all except one had been treated
prcviously with intermittent peritoneal dialysis or hcmodialysis.
Before the procedures described in the last section of Methods
werc pcrformcd, all paticnts had hccn stablc on CAPD treat-
ment for 2.5 to 15.5 months. During this period the mcan
hemoglobin concentration was 10.6 0.7 gIdl (8.6 0.1 to 12.7
0.4), and the mean serum creatinine 937 98 rmoles/liter
(590 28 to 1304 34) (mean SEM of 10 to 20 consecutive
measurements). The exchange procedures for all patients were
four 2-liter bags per day, that is, three 5-hr shifts during the day
and a 9-hr shift during the night.
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The three diabetic patients received insulin (insulin Actra-
pid®, Novo Industries A/S. Copenhagen, Denmark) via the
dialysate during the stable CAPD period. Individual doses were
injected directly into the dialysate bags and no subcutaneous
insulin was given. The individual doses were based on the
following procedures:
The daily insulin dose during CAPD was initially 2.5 times the
subcutaneous dose used before CAPD treatment. This dose was
divided equally and placed in each dialysate hag with a reduc-
tion of 25% in the bag used during the night. Dependent on the
blood glucose during the first week on CAPD, individual
adjustments of the initial insulin dose were made. After these
adjustments blood glucose concentrations were measured at 7
AM., 12 AM., 5 P.M., and 10 P.M. each day during 10 days of
treatment. Maxinial daily glucose variation was compared with
that for 10 consecutive days before the diabetic patients entered
the CAPD program and received insulin intermittently and
subcutaneously (Fig. I).
No subcutaneous insulin was given to any of these patients
during CAPD treatment, and the same amount of insulin was
given in bags containing 4,25 and 1.5% glucose solutions.
Radioactive insulin and concentration tneasuretnents. Insu-
lin concentration differences were measured with ('25I)monoio-
doinsulin® (Novo Industries A/S). The radioactive material was
produced and purified according to the methods of Jorgensen
and Binder [7], and counted with an automatic gamma counting
system (1185 Searle Analytic Inc., Chicago, illinois) with a
counting efficiency of 33%. All samples were counted twice for
20 mm. ('251)Insulin (20 to 30 mCi/mg) was dissolved in sterile
water giving 6.8 x 106 counts/20 mm/mI in experiment 1, 27.2 x
l0' counts/20 mm/mI in experiment 2, and 17.8 x 106 counts/20
mm/mI in the experiments described in the last section of
Methods.
Glucose concentration in plasma and dialysate was measured
using the oxidase method (Glue-DH-Method, Merck Darm-
stadt, West Germany), serum creatinine by an autoanalyzer
(Technicon, SMA II) and hemoglobin concentration by a
Coulter F analyzer (Coulter Electronics Ltd., Harpenden.
England).
Retention of ('251)insulin in the dialysate bags. Two experi-
ments (1 and 2, Fig. 2), using different doses of ('251)insulin and
conventional insulin, were carried out. Polyvinylchloride (PVC)
plastic bags with 4.25 and 1.5% glucose concentration in the
dialysate (Dienal®, Travenol Industries, Halden, Norway) were
used. Bags containing 4.25% glucose solutions had about a 15%
greater surface area than bags with 1 .5% glucose, hut all bags
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contained two liters of dialysate fluid. In experiment 1, a total of
four bags with 4.25% glucose and four bags with 1.5% glucose
were examined, and in experiment 2 a total of 20 bags (10 with
4.25% and 10 with 1.5% glucose) were used.
The experimental procedure during these investigations was
as follows: Four bags were heated to 38°C, then conventional
insulin (Insulin Actrapid®, Novo Industries A/S) was injected
into each bag, using 16 and 8 U in experiments I and 2,
respectively. After about 5 mm of mixing, a 1-mi syringe filled
with the dissolved ('251)insulin was injected into the bags, using
0.1 ml in experiment 1 and 0.2 ml in experiment 2 in each
dialysate bag. The bags were then shaken and left on a table for
20 mm before an initial sample of 10 ml (P values, Fig. 2,
experiment 1) was taken from each bag. The fluid bags were
then placed on hooks and emptied through the administration
tubing connected to the bags (surface area, about 12% of
dialysate bags). Total drainage time was adjusted to 15 mm by
the tubing roller clamps, and test samples (10 ml in experiment 1
and 5 ml in experiment 2) were taken from the distal end of the
tubing after a drainage time of 7 to 8 mm (D values in Fig. 2).
The temperature in the drained fluid was measured in a 10-ml
test tube.
To adjust for possible errors during proportioning of labelled
insulin and to get a more accurate value for the average amount
of (1251)insulin injected into each bag, 1-mi syringes filled with
0.4 ml (experiment 1) and 0.8 ml (experiment 2) of the dissolved
radioactive material were used. Twenty-five percent of the total
volume was placed in each of four counting tubes. The same
procedures were used for ('251)insulin distribution during the
investigations described in the last section of Methods and were
also employed as the basis for S values given in Figure 2. The
actual S value was found by using total count less background
(Ta) adjusted for different sampling volumes: S value = T x
sample volume (P and D)/2 liter.
Fig. 2. Recovery of ('251)insulin (mean 5EM) in drained dialysate
during two experimental periods (experiment 1,8 bags, and experiment
2, 20 bags) expressed in percent of that supplied into the bag (S =
100%). In experiment 1 the ratio between conventional insulin (units)
and radioactive insulin (counts/20 min/m!) was 2.35 x iO, while the
same ratio for experiment 2 was 0.15 x i0. P values were sampled from
the bag and D values from the distal end of the administration tubes.
Experiments with equal number 4.25 and 1.5% glucose containing
dialysate bags and the mean values for both solutions in each experi-
ment are shown.
All syringes (1 ml for injection and 10 ml for sampling) used
during the experiments were flushed with a 20% human albumin
solution (Albumin 20%®, Kabi AB, Stockholm, Sweden) to
minimize adsorption of ('251)insulin on the syringe wall.
Absorption of ('251)insulin from the peritoneal cavity. Each
patient was investigated on two consecutive days. During each
day of investigation the patients were subjected to five ex-
changes of dialysate during the day time with subsequent
dwelltimes (Td) of 30, 120, 60, 240 and 480 mm. It should be
noted that Td was measured from the start of infusion to the end
of drainage, hence including infusion and drainage. Dialysate
solutions containing 4.25% glucose were used for all exchanges
during day 1, while 1.5% glucose solutions were used on day 2
and during the night shift between the first and second days of
investigation.
During day time experiments, 2 liters of dialysate containing
both conventional and ('251)insulin was infused into the perito-
neal cavity. No subcutaneous insulin was given to any of the
patients. The dialysate was heated to 38°C and the procedures
for injection of insulin into the bags were similar to that
previously described for the bag-retention experiments. Each
diabetic patient received 16 U conventional insulin and 0.2 ml of
the dissolved ('251)insulin injected into each dialysate bag (same
for 4.25 and 1.5% glucose), hence no effort was made to
individualize the insulin supply to obtain adequate glucose
regulation. Nondiabetic patients got 8 U conventional insulin
and 0.2 ml of the dissolved ('251)insulin in each dialysate bag.
During the night between days 1 and 2, none of the patients
were administered labelled insulin in the dialysate, but the
diabetic patients received individual doses of insulin as previ-
ously described.
All patients fasted before beginning the exchange in the
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Fig. 1. Maximum daily blood glucose (z blood glucose) (mean sEM)
before and during CAPD in three diabetic patients. Measurements were
taken four times each day during 10 consecutive days in both periods.
During CAPD insulin was given via dialysate only.
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Fig. 4. Relative concentration, corrected for ultrafiltration volume, of
('251)-insulin (mean SaM) in the instilled dialysate (M), relative
concentration (activity) in blood (Ch/Cd) and ultrafiltration volume
(!V). The ('251)insulin values in blood (Ch) are related to the concentra-
tion in dialysate before installation (Cd). The M and V values include
both experimental days in all patients and are given as a function of Td.
hours
Fig. 3. Relative concentration, corrected for ultrafiltration volume, of
glucose (mean saM) in the instilled dialysate (M) as a function of
dwell-time (Td). The glucose values are given in percent of measured
concentration in dialysate before installation (Cd). In the diabetics (D)
separate values are given when using 4.25 and 1.5% glucose solutions.
In the nondiabetics (ND) one curve including both solutions is record-
ed. Hatched area designates the mean values for Td = 1 hr.
morning. They had a small breakfast during the second ex-
change (2 hr), lunch during the fourth exchange (4 hr), and a
small meal during the fifth exchange (8 hr).
During each of the experimental exchanges the following
fluid samples were taken from the dialysate to measure (1251)in-
sulin and glucose concentrations: (I) initial concentration (Cd)
collected 5 to 10 mm after start of infusion; (2) instilled
concentrations (C1) collected after a mixing procedure of suck-
ing and injection (via a 20-mi syringe), immediately after the end
of infusion; (3) end-concentration (Ci) collected S to 10 mm after
the beginning of fluid drainage.
All samples were withdrawn via a short connector supplied
with a two-way valve adapted directly to the peritoneal cathe-
ter. The sample volume for ('251)insulin measurements was 5
ml,
Blood samples for measurements of ('251)insulin and glucose
concentration (Cb) were taken before the first infusion proce-
dure each morning and between each exchange during the short
periods without fluid in the peritoneal cavity.
Drained fluid volume (Vd) was measured with a graduated
cylinder after each exchange, giving net ultrafiltration volume
( V) as the difference between Vd and the instilled volume, V0
(2 liters). The temperature in the drained fluid was measured in
a 10-mi test tube for each exchange.
Calculated values for absorption of ('2I)insulin and glucose
were based on the ratio of mass recovered in the drained fluid
(C x Vd) and the mass supplied through the instilled dialysate
(Cd x Vd0), thus taking differences in ultrafiltration into ac-
count. The formula used to calculate M or a relative concentra-
tion (Figs. 3, 4, and 5) was: M = Ct/Cd (1 + V/Vd0). The
fractional absorption (ABS) could then readily be evaluated as:
(l-M) x 100%, and the corresponding clearance (K) as: ABS x
Vd0/Td/100%.
Statistical calculations were based on a t distribution test for
means of two populations (Student t test).
Results
The maximum daily variation in blood glucose concentration
(z blood glucose) for the diabetic patients before the beginning
of and during CAPD treatment is shown in Figure 1. The
improved blood glucose regulation after the patients got a
continuous supply of insulin via the dialysate is highly signifi-
cant (P < 0.001). The initial daily insulin dose in dialysate of all
diabetic patients was 2.5 times the daily subcutaneous dose, but
the individual dose in dialysate after the adjustment period
varied as 2.4, 3.5, and 4.8 times the daily subcutaneous dose for
the three patients. The corresponding mean glucose concentra-
tions in the dialysate to achieve the needed ultrafiltration
volume were 50.4 12.6, 77.4 14.4, and 52.2 10.8 mmoles/
liter, hence there was no direct correlation between individual
dialyate dose/subcutaneous dose and the different amounts of
glucose in dialysate.
Figure 2 depicts the relationship between the amount of
('251)insulin injected into the dialysate bags (S value), its
concentration in the dialysate after injection (P values), and its
concentration in the dialysate from the distal end of the
administration tubing during fluid drainage (D value). No signif-
icant difference between the relative adsorption of ('251)insulin
on the plastic bags in the two experiments was detected, that is,
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D value/S value was 34 5% in experiment 1 and 36 3% in
experiment 2. There was no significant difference between bags
containing 4.25 or 1.5% glucose nor any difference between P
and D values experiment 1 (P/S = 36 4%), hence all
adsorption of radioactive insulin occurred in the bags and not in
the tubing.
For all experiments on intraperitoneal ('251)insulin adminis-
tration the mean (± 5EM) infusion time was 13.0 0.4 mm, and
the mean drainage time was 17.3 0.5 mm, hence all experi-
mental points referred to Td = 30 mm were the results of
exchanges where bag drainage started immediately after the end
of infusion.
The mean temperature in the drained fluid from the bags was
35.9 0.1°C and in the drained fluid from the peritoneal cavity
37.2 0.1°C.
Figure 3 shows the absorption of glucose from the peritoneal
cavity as a function of dwell-time (Td) for the diabetic (D) and
the nondiabetic (ND) patients.
For Td = 1 hr, the glucose absorption in the diabetic group
was significantly higher (P < 0.05) when using 4.25% compared
to 1.5% glucose in the dialysate (35 2% and 22 1%,
respectively). The mean values for glucose absorption in the
diabetic patients were 56 3% after 4 hr and 76 5% after 8 hr
installation. In the nondiabetics, no differences in the glucose
absorption were found when using the two different glucose
solutions. The mean glucose absorption values for the nondia-
betics were 29 4% after 1 hr, 74 4% after 4 hr and 86 3%
after 8 hr. The differences in glucose absorption between
diabetics and nondiabetics after 4 and 8 hr was significant (P <
0.05). Initial glucose concentration (Cd) was 194 3.2 mmoles/
liter in the experiments with 4.25% and 73 1.6 mmoles/liter
with 1.5% glucose solutions.
As shown in Figure 4 the (1251)insulin absorption was higher
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Fig. 5. Relative concentration, corrected for ultrafiltration volume, of
('251)-insulin (mean SEM) in the instilled dialysate (M) in diabetic (D)
and nondiabetic (ND) patients. Separate values for 4.25 and 1.5%
glucose solutions are given for the whole group of patients (D + ND).
The values are given as a function of Td.
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Fig. 6. Changes in blood glucose concentration (mean SEM) during
the day for diabetic (D) and nondiabetic (ND) patients. Dotted lines
refer to 4.25 or 1.5% dialysate and full lines give the average of these.
The values are given as a function of the time from the start of the first
shift in the morning, hence not directly correlated to dwell-time.
after 30 mm (14 5%) than after 1 hr (2.8 5.4%). This
difference was only slightly significant (P < 0.25). The absorp-
tion of insulin was 21 9% after 2 hr, 28 9% after 4 hr, and 46
6% after 8 hr installation. The mean ratio for Cl/Cd (D in Fig.
4) was the same for all patients on the first and second day of
investigation (0.99 0.04 and 1.06 0.04, respectively).
The concentration of labelled insulin in blood increased
almost linearly in all patients. The ratio (Cb/Cd (Fig. 4) in-
creased from zero to 0.09 0.01 during the first day, and from
0.06 0.01 to 0.12 0.02 at the end of the last shift of the
second day. There was no significant difference between diabet-
ic and nondiabetic patients with regard to the accumulation of
('251)insulin in blood.
Calculated mean ('251)insulin clearance for Td =2, 4, and 8 hr
was 3.5, 2.3, and 1.9 mi/mm, respectively. There was no
difference in ('251)insulin absorption from the peritoneal cavity
for any dwell-time when using 4.25 or 1.5% glucose solutions
(Fig. 5). For Td = 30 mm a slightly higher absorption (P < 0.25)
could be seen in the diabetic (22 6%) as compared to
nondiabetic (6 8%) patients.
Figure 6 shows mean blood glucose concentrations for the
diabetic and nondiabetic patients during the two experimental
days. In the nondiabetics the blood glucose concentration
increased during 30 mm (first exchange) and 1-hr (third ex-
change) installations. For dwell-times longer than 2 hr, the
blood glucose values decreased. In the diabetic group, the
glucose load surpassed the insulin transport during the first 2 hr
(first, second, and third exchange) leading to increasing blood
glucose concentration. For longer dwell-times steady state
glucose values were obtained when using 4.25% and a small
decrease when using 1.25% glucose in dialysate. The relatively
small dose conventional insulin used in this experiment and the
individual need of exogenous insulin have, however, to be
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taken in consideration. This was reflected in the differences
between mean blood glucose values for diabetic and nondiabet-
ic patients.
Discussion
During CAPD treatment in diabetic patients, a normalization
of daily blood glucose variations can be achieved using continu-
ous intraperitoneal supply of insulin via the dialysate with no
subcutaneous injections (Fig. 1). The insulin doses must he
individualized but there is no direct correlation between the
individual dose and the different amounts of glucose in the
dialysate. The same insulin dose can he used for each installa-
tion, disregarding daily dift'erences in dialysate glucose content
and changes due to varying needs of ultrafiltration. During the
nightshift lower dose was used about 25% lower than the dose
used during the day. The individual daily insulin dose for each
patient was based on experience from the initial CAPD training
period. The individual requirement of insulin varied considera-
bly more when insulin was given in the dialysate than by
subcutaneous administration (Fig. 1). The improved clinical
results are in agreement with findings in healthy, insulin-
dependent diabetic patients treated with continuous infusion of
insulin, delivered into the peritoneal cavity [8, 9].
During CAPD the easiest method of supplying insulin is to
inject the hormone into the dialysate bag. Insulin adsorption
rate from conventional, parenteral, administration equipment
has been described but the results are conflicting [101. About
65% of('251)insulin was left in the bag in our study, independent
of the different ratios between the added doses of labelled and
unlabelled insulin used (Fig. 2). Lack of proportional insulin
adsorption to different surface areas as demonstrated by equal
adsorption in 4.25 and 1.5% glucose bags has also been found
by others [10]. The negligible adsorption of (1251)insulin in the
administration tubing (difference between P and D values, Fig.
2) could be a "wash out" effect caused by continuous dialysate
flow through the line.
The higher intraperitoneal absorption of glucose in the nondi-
abetie as compared to the diabetic patients (Fig. 3) for Td =4
and 8 hr could be explained by a high blood glucose concentra-
tion in the last group during the two experimental days (Fig. 6).
By optimal insulin dosage and normalization of the blood
glucose concentrations, this difference should he minimal,
hence the absorption in the diabetic patients should be the same
as for the nondiabetie patients. The higher absorption of
glucose in the diabetic group for Td = I hr, when using 4.25%
glucose solution compared to 1.5%, is likewise caused by
differences in the concentration gradient between dialysate and
blood, that is, for Td = 1 hr the ratio Cd/Cb = 7.8 1.1 for
4.25%, and 4.9 0.5 for 1.5% glucose in the dialysate. It is
expected that glucose absorption surpasses the insulin absorp-
tion for dwell-times up to 1 hr more or less independent of
insulin dosage. Thus, adequate glucose regulation in diabetic
patients during IPD treatment is difficult to achieve. For
nondiaheties (also expected for diabetic patients with adequate
glucose regulation on CAPD treatment) the daily glucose load
(correlated to measured Cd) using four dialysis shifts per day (5
+ 5 + 5 + 9 hr dwell-time) will be 85 to 225 g, depending on the
glucose solutions used.
The use of (1251)insulin instead of the natural hormone to
study intraperitoneal insulin absorption was based on reports
showing that the method of iodination and purification should
not alter its biological activity [II, 12].
The mean intraperitoneal absorption curve for (1251)insulin
(Fig. 4) for Td = 5 hr shows an absorption of 32.5%, while linear
extrapolation to Td = 9 hr gives about 50% absorption. Using
four exchanges per day, about 37% of the insulin installed in the
peritoneal cavity will be absorbed but only about 13% of that
initially injected into the dialysate bag. This daily absorbed dose
is about 46% of the mean subcutaneous insulin dose used before
CAPD treatment is begun (Fig. 1). Taking the high glucose load
during CAPD into account, this should suggest an overall
economic utilization of the insulin delivered via the peritoneal
cavity.
Some of the radioactivity in the drained dialysate could
represent degraded insulin or returned intact insulin. Degraded
insulin is dissociated from the specific receptors on the cell
surface after endocytologic internalization of insulin [13], This
latter lysosomal pathway is claimed to be unrelated to insulin
activation of glucose transport [13] and could account for a loss
of biological active insulin. Results from column chromatogra-
phy of effluent, peritoneal dialysate, give no evidence of
degraded insulin in the drained peritoneal fluid [14]. It is more
likely that the almost linear accumulation of measured radioac-
tivity in blood from the start of the first day to the end of the
second day of ('251)insulin use represents degraded insulin. No
experience from the routine CAPD treatment suggested any
problems with the biological effect of accumulated insulin as
reported by others [14]. If some of the recovered insulin in the
effluate represents insulin accumulated in the peritoneal cavity
from earlier installations, this should give increasing Cl/Cdratio
from the first installation to the end of the experiment. No such
differences were found.
The suggested higher intraperitoneal absorption of labelled
insulin after 30 mm as compared to 1 hr (Fig. 4), and the slightly
higher 30 mm absorption in the diabetics compared to the
nondiabetics (Fig. 5), can give information on insulin-receptor
binding and faetnrs influencing this binding. The subsequent
release of insulin into the fluid from Td = 30 mm to Td = 1 hr
can be related to interaction between insulin and its receptors as
an association/dissociation phenomenon. As reported there are
fast and slow binding insulin receptors [15]. Only intact insulin
dissociates from the low affinity (fast dissociating) state of the
receptor [15]. This binding decreases with increasing tempera-
ture [13, 16, 17], hence the relatively low temperature of the
infused fluid (initial temperature 35.9 0.1°C) can theoretically
in part explain a dissociation phenomenon. Changes in pH in
the fluid can also influence this binding [16].
Concerning the indicated difference in ('251)insulin absorption
between diabetics and nondiabetics for Td = 30 mm (Fig. 5), it
has been shown by studies in vitro, on obese mice and on
obese, noninsulin-dependent diabetic patients [16, 18—20] that
the efficacy of the insulin receptors decreases with the increas-
ing level of insulin saturation, that is, the number of insulin-
receptors decreases during periods of chronic hyperinsuline-
mia. The CAPD treatment includes a very high daily glucose
load (Fig. 3), and it could be that this leads to chronic
hyperinsulinemia in the nondiabetie patients resulting in de-
creased binding of exogenous insulin.
Another possible problem with this continuous glucose load
is related to findings by others that a high glucose load
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decreases the insulin response as a result of exhausted beta islet
cells [21].
The higher doses of conventional insulin used in the diabetic
as compared to the nondiabetic group do not seem to influence
insulin absorption. After 60 mm installation the (1251)insulin
absorption was linear as expected for diffusible transport, and
these clearance values are in agreement with theoretical calcu-
lations from kinetic studies [22] and values found in animal
experiments [14].
No attempts were made to normalize the blood glucose in the
diabetic patients during the two experimental days (Fig. 6). As
mentioned the fast absorption of glucose within the first 2 hr
exceeds the insulin absorption but during longer installations
the insulin effect is stable (Figs. 3, 4, and 6) independent of food
intake. In the diabetic group the higher blood glucose concen-
tration, compared to nondiabetics when using 4.25 and 1.5%
glucose solutions, should require higher doses of exogenous
insulin. When the insulin dose is adjusted to individual needs,
the differences between 1.5 and 4.25% glucose solutions for
diabetics should be minimal as indicated by the blood glucose
curves for nondiabetics (Fig. 6) and the maximum daily blood
glucose variation during routine CAPD treatment (Fig. 1).
It should be noted that individual insulin-doses can be
correlated to the ultrafiltration capacity, that is, individual
variations in peritoneal membrane permeability, and to changes
in the permeability during peritonitis [23]. Varying needs of
exogenous insulin during CAPD treatment for a given patient
are to some extent dependent on the requirement for glucose in
the dialysate but to a higher degree on the clinical effect of
CAPD treatment.
Summary. The blood glucose regulation in three diabetic
patients on continuous ambulatory peritoneal dialysis (CAPD)
with insulin supplied via the dialysate was studied. Using a
mean daily dose of the hormone in the dialysate bags (without
subcutaneous injections) of 107.3 26.6 U, the patients showed
improved blood glucose regulation as compared to a period with
intermittent and subcutaneous insulin supply before entering
the CAPD program. Based on (1251)insulin measurements, 65%
of the insulin injected into the dialysate bags was retained and
only 35% entered the peritoneal cavity during the infusion of
dialysate fluid. No difference between 4.25 and 1.5% glucose
containing dialysate bags, or any additional adsorption in the
administration tubes was found. ('251)insulin absorption from
instilled dialysate in the peritoneal cavity as a function of dwell-
time (Td) was evaluated in three diabetic and three nondiabetic
patients on CAPD. For Td = 0.5 hr, the mean absorption for all
patients was slightly higher (P < 0.25) than for Td = 1 hr. In the
diabetics compared to the nondiabetics the mean (1251)insulin
absorption was slightly higher by Td = 0.5 hr (P <0.25). These
differences do suggest an insulin receptor interaction. For Td >
1 hr there was no significant difference between patient groups,
and the mean absorption of insulin could be correlated with
diffusive/convective transport. Mean absorption of ('251)insulin
was 21 9%, 28 9%, and 46 6% by T = 2, 4, and 8 hr,
respectively. By four exchanges of dialysate per day about 37%
of the instilled insulin was absorbed, which is only 13% of that
injected into the dialysate bags. This insulin absorption from the
peritoneal cavity corresponds to 46% of the subcutaneous dose
used before CAPD treatment. At normal blood glucose concen-
tration the glucose absorption from the instilled dialysate was
74 4% and 86 3% T = 4 and 8 hr, respectively. It was
concluded that the utilization of insulin and glucose supplied to
the peritoneal cavity was adequate and no additional exogenous
nsulin was needed in diabetic patients on CAPD treatment.
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